Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vitamin B3 (nicotinamide) to prevent major adverse kidney events in septic shock
2020-001276-15Phase 3Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in septic shock and acute kidney failure (AKF) comparing Nicotinamide with Placebo (2 arms). Primary endpoint: MAKE30 composite outcome. Started Apr 2020; status: active.
02
Drugs
nicotinamide
03
Conditions
septic shockacute kidney failure (AKF)
Beyond the preview
Go deeper on 2020-001276-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001276-15.